Review article: The management of autoimmune hepatitis beyond consensus guidelines

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 4, 2013, Pages 343-364

  Czaja, A J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BUDESONIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; MERCAPTOPURINE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITROFURANTOIN; PREDNISOLONE; PREDNISONE; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ANEMIA; ARTHRALGIA; AUTOIMMUNE HEPATITIS; BILE DUCT INJURY; BONE MARROW SUPPRESSION; CAUCASIAN; CHOLESTASIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOPENIA; DIARRHEA; DISEASE SURVEILLANCE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOGRAPHY; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; FEVER; HEALTH CARE ORGANIZATION; HISTOPATHOLOGY; HUMAN; INDIVIDUALIZATION; LEUKOPENIA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER NECROSIS; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; MEDICAL SOCIETY; NAUSEA; NEUROLOGIC DISEASE; PATIENT CARE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; QUALITY CONTROL; RACE DIFFERENCE; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TERATOGENICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84880252656     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12381     Document Type: Review

References (208)

1. Alvarez F, Berg PA, Bianchi FB, et al,. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
2. Hennes EM, Zeniya M, Czaja AJ, et al,. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76.
3. Manns MP, Czaja AJ, Gorham JD, et al,. Practice Guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
4. Gleeson D, Heneghan MA,. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60: 1611-29.
5. Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E,. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374-85.
6. Czaja AJ,. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol 2010; 16: 934-47.
7. Czaja AJ, Manns MP,. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology 2010; 139: 58-72.
8. Czaja AJ,. Autoimmune hepatitis in diverse ethnic populations and geographical regions. Expert Rev Gastroenterol Hepatol 2013; 7: 365-85.
9. Lamers MM, van Oijen MG, Pronk M, Drenth JP,. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol 2010; 53: 191-8.
10. Bjornsson E, Talwalkar J, Treeprasertsuk S, Neuhauser M, Lindor K,. Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis. Clin Gastroenterol Hepatol 2011; 9: 57-63.
11. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY,. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004; 2: 625-31.
12. Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM,. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology 1997; 113: 664-8.
13. Stravitz RT, Lefkowitch JH, Fontana RJ, et al,. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology 2011; 53: 517-26.
14. Czaja AJ, Carpenter HA,. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001; 34: 659-65.
15. Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB,. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int 2004; 24: 322-9.
16. Fujiwara K, Fukuda Y, Yokosuka O,. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. J Gastroenterol 2008; 43: 951-8.
17. Suzuki A, Brunt EM, Kleiner DE, et al,. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011; 54: 931-9.
18. Efe C, Ozaslan E, Purnak T, Ozseker B, Kav T, Bayraktar Y,. Liver biopsy is a superior diagnostic method in some patients showing the typical laboratory features of autoimmune hepatitis. Clin Res Hepatol Gastroenterol 2012; 36: 185-8.
19. Czaja AJ,. Acute and acute severe (fulminant) autoimmune hepatitis. Dig Dis Sci 2013; 58: 897-914.
20. Viruet EJ, Torres EA,. Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J 1998; 17: 297-300.
21. Yasui S, Fujiwara K, Yonemitsu Y, Oda S, Nakano M, Yokosuka O,. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol 2011; 46: 378-90.
22. Abe M, Hiasa Y, Masumoto T, et al,. Clinical characteristics of autoimmune hepatitis with histological features of acute hepatitis. Hepatol Res 2001; 21: 213-9.
23. Carpenter HA, Czaja AJ,. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002; 6: 685-705.
24. Yasui S, Fujiwara K, Okitsu K, Yonemitsu Y, Ito H, Yokosuka O,. Importance of computed tomography imaging features for the diagnosis of autoimmune acute liver failure. Hepatol Res 2012; 42: 42-50.
25. Czaja AJ, Rakela J, Ludwig J,. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988; 95: 448-53.
26. Yeoman AD, Westbrook RH, Zen Y, et al,. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011; 53: 926-34.
27. Okano N, Yamamoto K, Sakaguchi K, et al,. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003; 25: 263-70.
28. Miyake Y, Iwasaki Y, Terada R, et al,. Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol Res 2007; 37: 801-5.
29. Czaja AJ, Carpenter HA,. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824-32.
30. Singh R, Nair S, Farr G, Mason A, Perrillo R,. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol 2002; 97: 2670-3.
31. Ichai P, Duclos-Vallee JC, Guettier C, et al,. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13: 996-1003.
32. Ludwig J, Czaja AJ, Dickson ER, LaRusso NF, Wiesner RH,. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. Liver 1984; 4: 105-16.
33. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB,. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000; 31: 1231-8.
34. Czaja AJ,. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci 2013; 58: 326-43.
35. D'Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR,. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int 2005; 25: 325-30.
36. Czaja AJ, Manns MP, Homburger HA,. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992; 103: 1290-5.
37. Gupta R, Agarwal SR, Jain M, Malhotra V, Sarin SK,. Autoimmune hepatitis in the Indian subcontinent: 7 years experience. J Gastroenterol Hepatol 2001; 16: 1144-8.
38. Baeres M, Herkel J, Czaja AJ, et al,. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002; 51: 259-64.
39. Abe M, Mashiba T, Zeniya M, Yamamoto K, Onji M, Tsubouchi H,. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol 2011; 46: 1136-41.
40. Czaja AJ, Souto EO, Bittencourt PL, et al,. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002; 37: 302-8.
41. Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG,. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002; 50: 713-7.
42. Radha Krishna Y, Saraswat VA, Das K, et al,. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. Liver Int 2009; 29: 392-8.
43. Lal J, Thapa BR, Rawal P, Ratho RK, Singh K,. Predictors of outcome in acute-on-chronic liver failure in children. Hepatol Int 2011; 5: 693-7.
44. Gregorio GV, Portmann B, Karani J, et al,. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33: 544-53.
45. Lim KN, Casanova RL, Boyer TD, Bruno CJ,. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol 2001; 96: 3390-4.
46. Verma S, Torbenson M, Thuluvath PJ,. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology 2007; 46: 1828-35.
47. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C,. The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol 2012; 46: 155-61.
48. Carrion AF, Ghanta R, Carrasquillo O, Martin P,. Chronic liver disease in the Hispanic population of the United States. Clin Gastroenterol Hepatol 2011; 9: 834-41.
49. Pando M, Larriba J, Fernandez GC, et al,. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999; 30: 1374-80.
50. Miyake Y, Iwasaki Y, Kobashi H, et al,. Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. Hepatol Int 2009; 3: 556-62.
51. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ,. AASLD Practice Guidelines. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.
52. Chapman R, Fevery J, Kalloo A, et al,. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-78.
53. Czaja AJ,. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011; 56: 958-76.
54. Bjornsson E, Talwalkar J, Treeprasertsuk S, et al,. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51: 2040-8.
55. Roberts SK, Therneau TM, Czaja AJ,. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-57.
56. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R,. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983; 3: 685-9.
57. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007; 27: 507-15.
58. Rockey DC, Seeff LB, Rochon J, et al,. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010; 51: 2117-26.
59. Lucena MI, Kaplowitz N, Hallal H, et al,. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol 2011; 55: 820-7.
60. Beuers U, Boberg KM, Chapman RW, et al,. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.
61. Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R,. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301.
62. Kuiper EM, Zondervan PE, van Buuren HR,. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2010; 8: 530-4.
63. Perdigoto R, Carpenter HA, Czaja AJ,. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992; 14: 325-31.
64. Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ,. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008; 47: 949-57.
65. Kim WR, Ludwig J, Lindor KD,. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol 2000; 95: 1130-8.
66. Angulo P, Maor-Kendler Y, Lindor KD,. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002; 35: 1494-500.
67. Muratori P, Muratori L, Gershwin ME, et al,. 'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clin Exp Immunol 2004; 135: 154-8.
68. Sherlock S,. Ludwig Symposium on biliary disorders. Autoimmune cholangitis: a unique entity? Mayo Clin Proc 1998; 73: 184-90.
69. Kenny RP, Czaja AJ, Ludwig J, Dickson ER,. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci 1986; 31: 705-11.
70. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM,. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992; 2: 148-59.
71. Otterness D, Szumlanski C, Lennard L, et al,. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 60-73.
72. Weinshilboum R,. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001; 29: 601-5.
73. Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM,. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990; 30: 358-63.
74. Allison AC,. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000; 47: 63-83.
75. Dubinsky MC,. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004; 2: 731-43.
76. Atreya I, Neurath MF,. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications. Expert Rev Gastroenterol Hepatol 2008; 2: 23-34.
77. Thomas CW, Myhre GM, Tschumper R, et al,. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther 2005; 312: 537-45.
78. Tiede I, Fritz G, Strand S, et al,. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-45.
79. Steel AW, Mela CM, Lindsay JO, Gazzard BG, Goodier MR,. Increased proportion of CD16(+) NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment. Aliment Pharmacol Ther 2011; 33: 115-26.
80. Ben Ari Z, Mehta A, Lennard L, Burroughs AK,. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995; 23: 351-4.
81. Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM,. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004; 2: 410-7.
82. Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG,. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002; 37: 441-7.
83. Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA,. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006; 45: 584-91.
84. Czaja AJ, Carpenter HA,. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006; 51: 968-75.
85. Black AJ, McLeod HL, Capell HA, et al,. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716-8.
86. Yates CR, Krynetski EY, Loennechen T, et al,. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-14.
87. Sahasranaman S, Howard D, Roy S,. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008; 64: 753-67.
88. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE,. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994; 55: 15-20.
89. Pettersson B, Almer S, Albertioni F, Soderhall S, Peterson C,. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Ther Drug Monit 2002; 24: 351-8.
90. Kaskas BA, Louis E, Hindorf U, et al,. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52: 140-2.
91. Lichtenstein GR,. Use of laboratory testing to guide 6-mercaptopurine/ azathioprine therapy. Gastroenterology 2004; 127: 1558-64.
92. Regueiro M, Mardini H,. Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. J Clin Gastroenterol 2002; 35: 240-4.
93. Nguyen TM, Daubard M, Le Gall C, Larger M, Lachaux A, Boulieu R,. Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis. Ther Drug Monit 2010; 32: 433-7.
94. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y,. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002; 35: 75-81.
95. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ,. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62.
96. Czaja AJ,. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009; 29: 816-23.
97. Czaja AJ, Davis GL, Ludwig J, Taswell HF,. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984; 4: 622-7.
98. Czaja AJ, Menon KV, Carpenter HA,. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002; 35: 890-7.
99. van Gerven NM, Verwer BJ, Witte BI, et al,. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013; 58: 141-7.
100. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A,. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510-6.
101. Miyake Y, Iwasaki Y, Terada R, et al,. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005; 43: 951-7.
102. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102: 1005-12.
103. Czaja AJ, Ammon HV, Summerskill WH,. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980; 78: 518-23.
104. Czaja AJ, Wolf AM, Baggenstoss AH,. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981; 80: 687-92.
105. Luth S, Herkel J, Kanzler S, et al,. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 2008; 42: 926-30.
106. Czaja AJ,. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Dig Dis Sci 2010; 55: 1761-9.
107. Czaja AJ,. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci 2012; 57: 1996-2010.
108. Kanzler S, Gerken G, Lohr H, Galle PR, Meyer zum Buschenfelde KH, Lohse AW,. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001; 34: 354-5.
109. Selvarajah V, Montano-Loza AJ, Czaja AJ,. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther 2012; 36: 691-707.
110. Johnson PJ, McFarlane IG, Williams R,. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-63.
111. Czaja AJ,. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990; 11: 1044-9.
112. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007; 46: 1138-45.
113. Schalm SW, Ammon HV, Summerskill WH,. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976; 8: 221-7.
114. Czaja AJ, Carpenter HA,. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005; 39: 819-25.
115. Czaja AJ,. Autoimmune hepatitis: focusing on treatments other than steroids. Can J Gastroenterol 2012; 26: 615-20.
116. Martinez-Martinez S, Redondo JM,. Inhibitors of the calcineurin/NFAT pathway. Curr Med Chem 2004; 11: 997-1007.
117. Mistilis SP, Vickers CR, Darroch MH, McCarthy SW,. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust 1985; 143: 463-5.
118. Hyams JS, Ballow M, Leichtner AM,. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987; 93: 890-3.
119. Person JL, McHutchison JG, Fong TL, Redeker AG,. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol 1993; 17: 317-20.
120. Sherman KE, Narkewicz M, Pinto PC,. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994; 21: 1040-7.
121. Jackson LD, Song E,. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995; 36: 459-61.
122. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL,. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999; 94: 241-8.
123. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M,. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001; 46: 1321-7.
124. Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O,. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999; 135: 111-4.
125. Alvarez F, Ciocca M, Canero-Velasco C, et al,. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999; 30: 222-7.
126. Cuarterolo M, Ciocca M, Velasco CC, et al,. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006; 43: 635-9.
127. Van Thiel DH, Wright H, Carroll P, et al,. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 771-6.
128. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC,. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38: 805-9.
129. Larsen FS, Vainer B, Eefsen M, Bjerring PN,. Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13: 3232-6.
130. Hess AD, Fischer AC, Horwitz LR, Laulis MK,. Cyclosporine-induced autoimmunity: critical role of autoregulation in the prevention of major histocompatibility class II-dependent autoaggression. Transplant Proc 1993; 25: 2811-3.
131. Lohse AW, Weiler-Norman C, Burdelski M,. De novo autoimmune hepatitis after liver transplantation. Hepatol Res 2007; 37 (Suppl. 3): S462.
132. Czaja AJ,. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Dig Dis Sci 2012; 57: 2248-66.
133. Serkova NJ, Christians U, Benet LZ,. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv 2004; 4: 97-107.
134. Wu Q, Marescaux C, Wolff V, et al,. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Eur Neurol 2010; 64: 169-77.
135. Allison AC, Eugui EM,. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
136. Allison AC,. Mechanisms of action of mycophenolate mofetil. Lupus 2005; 14 (Suppl. 1): s2-8.
137. Richardson PD, James PD, Ryder SD,. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 371-5.
138. Devlin SM, Swain MG, Urbanski SJ, Burak KW,. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004; 18: 321-6.
139. Chatur N, Ramji A, Bain VG, et al,. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005; 25: 723-7.
140. Inductivo-Yu I, Adams A, Gish RG, et al,. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007; 5: 799-802.
141. Hennes EM, Oo YH, Schramm C, et al,. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008; 103: 3063-70.
142. Hlivko JT, Shiffman ML, Stravitz RT, et al,. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6: 1036-40.
143. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G,. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009; 51: 156-60.
144. Wolf DC, Bojito L, Facciuto M, Lebovics E,. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci 2009; 54: 2519-22.
145. Sharzehi K, Huang MA, Schreibman IR, Brown KA,. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010; 24: 588-92.
146. Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al,. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011; 34: 335-43.
147. Czaja AJ,. Drug choices in autoimmune hepatitis: Part B-nonsteroids. Expert Rev Gastroenterol Hepatol 2012; 6: 617-35.
148. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN,. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 2011; 55: 636-46.
149. Klieger-Grossmann C, Chitayat D, Lavign S, et al,. Prenatal exposure to mycophenolate mofetil: an updated estimate. J Obstet Gynaecol Can 2010; 32: 794-7.
150. Heneghan MA, Al-Chalabi T, McFarlane IG,. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother 2006; 7: 145-56.
151. Czaja AJ,. Drug choices in autoimmune hepatitis: part A-steroids. Expert Rev Gastroenterol Hepatol 2012; 6: 603-15.
152. Clissold SP, Heel RC,. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984; 28: 485-518.
153. Manns MP, Woynarowski M, Kreisel W, et al,. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-206.
154. Danielsson A, Prytz H,. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8: 585-90.
155. Wiegand J, Schuler A, Kanzler S, et al,. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005; 25: 927-34.
156. Csepregi A, Rocken C, Treiber G, Malfertheiner P,. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006; 12: 1362-6.
157. Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW,. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol. 2001; 39: 339-41.
158. Longui CA, Santos MC, Formiga CB, et al,. Antiproliferative and apoptotic potencies of glucocorticoids: nonconcordance with their antiinflammatory and immunosuppressive properties. Arq Bras Endocrinol Metabol 2005; 49: 378-83.
159. Hofkens W, van den Hoven JM, Pesman GJ, et al,. Safety of glucocorticoids can be improved by lower yet still effective dosages of liposomal steroid formulations in murine antigen-induced arthritis: comparison of prednisolone with budesonide. Int J Pharm 2011; 416: 493-8.
160. Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S,. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003; 9: 2681-5.
161. Efe C, Ozaslan E, Kav T, et al,. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev 2012; 11: 330-4.
162. Czaja AJ, Lindor KD,. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000; 119: 1312-6.
163. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA,. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A 2009; 149A: 1241-8.
164. Czaja AJ,. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009; 51: 161-7.
165. Czaja AJ, Carpenter HA,. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 532-8.
166. Czaja AJ, Donaldson PT, Lohse AW,. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413-9.
167. Efe C, Ozaslan E, Wahlin S, et al,. Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study. Liver Int 2013; 33: 190-6.
168. Ma Y, Okamoto M, Thomas MG, et al,. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-64.
169. Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ,. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 2012; 32: 85-92.
170. Maggiore G, Bernard O, Homberg JC, et al,. Liver disease associated with anti-liver-kidney microsome antibody in children. J Pediatr 1986; 108: 399-404.
171. Homberg JC, Abuaf N, Bernard O, et al,. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987; 7: 1333-9.
172. Miyake Y, Iwasaki Y, Kobashi H, et al,. Clinical features of type 1 autoimmune hepatitis in adolescence and early adulthood. Hepatol Res 2009; 39: 766-71.
173. Rosenkrantz JG, Githens JH, Cox SM, Kellum DL,. Azathioprine (Imuran) and pregnancy. Am J Obstet Gynecol 1967; 97: 387-94.
174. de Boer NK, Jarbandhan SV, de Graaf P, Mulder CJ, van Elburg RM, van Bodegraven AA,. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 2006; 101: 1390-2.
175. Candia L, Marquez J, Espinoza LR,. Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma. Semin Arthritis Rheum 2005; 35: 49-56.
176. Heneghan MA, Norris SM, O'Grady JG, Harrison PM, McFarlane IG,. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001; 48: 97-102.
177. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH,. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 9-17.
178. Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW,. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006; 101: 556-60.
179. Werner M, Bjornsson E, Prytz H, et al,. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol 2007; 42: 986-91.
180. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH,. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975; 16: 876-83.
181. Soloway RD, Summerskill WH, Baggenstoss AH, et al,. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-33.
182. Seela S, Sheela H, Boyer JL,. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int 2005; 25: 734-9.
183. Whitacre CC, Reingold SC, O'Looney PA,. A gender gap in autoimmunity. Science 1999; 283: 1277-8.
184. Buchel E, Van Steenbergen W, Nevens F, Fevery J,. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 2002; 97: 3160-5.
185. Wang KK, Czaja AJ,. Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. Hepatology 1988; 8: 1679-83.
186. Park SZ, Nagorney DM, Czaja AJ,. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 2000; 45: 1944-8.
187. Yeoman AD, Al-Chalabi T, Karani JB, et al,. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008; 48: 863-70.
188. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008; 103: 1944-51.
189. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C,. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci 2011; 56: 578-85.
190. Yang JD, Kim WR,. Surveillance for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10: 16-21.
191. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
192. EASL-EORTC. EASL-EORTC clinical practice guidelines management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
193. Bolondi L, Sofia S, Siringo S, et al,. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251-9.
194. Kim CK, Lim JH, Lee WJ,. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med 2001; 20: 99-104.
195. Singal A, Volk ML, Waljee A, et al,. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47.
196. Forner A, Reig M, Bruix J,. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology 2009; 137: 26-9.
197. El-Serag HB, Kanwal F,. alpha-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it. Clin Gastroenterol Hepatol 2013; 11: 441-3.
198. Sato T, Tateishi R, Yoshida H, et al,. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int 2009; 3: 544-50.
199. Sherman M,. Serological surveillance for hepatocellular carcinoma: time to quit. J Hepatol 2010; 52: 614-5.
200. Lok AS, Sterling RK, Everhart JE, et al,. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502.
201. Zhang BH, Yang BH, Tang ZY,. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-22.
202. Marrero JA, El-Serag HB,. Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology 2011; 53: 1060-1.
203. Poon D, Anderson BO, Chen LT, et al,. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10: 1111-8.
204. Sherman M, Bruix J, Porayko M, Tran T,. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 2012; 56: 793-6.
205. Davila JA, Weston A, Smalley W, El-Serag HB,. Utilization of screening for hepatocellular carcinoma in the United States. J Clini Gastroenterol 2007; 41: 777-82.
206. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB,. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010; 52: 132-41.
207. Davila JA, Henderson L, Kramer JR, et al,. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011; 154: 85-93.
208. Lederle FA, Pocha C,. Screening for liver cancer: the rush to judgment. Ann Int Med 2012; 156: 387-9.